Aclaris Therapeutics (ACRS) Accumulated Depreciation & Amortization (2017 - 2025)
Historic Accumulated Depreciation & Amortization for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $5.0 million.
- Aclaris Therapeutics' Accumulated Depreciation & Amortization rose 649.57% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 649.57%. This contributed to the annual value of $4.8 million for FY2024, which is 1544.93% up from last year.
- Latest data reveals that Aclaris Therapeutics reported Accumulated Depreciation & Amortization of $5.0 million as of Q3 2025, which was up 649.57% from $5.0 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Accumulated Depreciation & Amortization peaked at $5.0 million during Q2 2025, and registered a low of $2.9 million during Q1 2021.
- In the last 5 years, Aclaris Therapeutics' Accumulated Depreciation & Amortization had a median value of $4.2 million in 2023 and averaged $4.1 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first soared by 2935.57% in 2021, then soared by 165.07% in 2024.
- Over the past 5 years, Aclaris Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $3.4 million in 2021, then grew by 18.92% to $4.0 million in 2022, then grew by 3.15% to $4.2 million in 2023, then increased by 15.45% to $4.8 million in 2024, then rose by 3.73% to $5.0 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $5.0 million for Q3 2025, versus $5.0 million for Q2 2025 and $4.9 million for Q1 2025.